A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

ClinicalTrials.gov ID: NCT04486352

Public ClinicalTrials.gov record NCT04486352. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 6:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer

Study identification

NCT ID: NCT04486352
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Enrollment: 148 participants

Conditions and interventions

Conditions

Endometrial Cancer

Interventions

Abemaciclib Drug
Atezolizumab - 21 Day Cycle Drug
Atezolizumab - 28 Day Cycle Drug
Bevacizumab Drug
Giredestrant Drug
Inavolisib Drug
Ipatasertib Drug
Letrozole Drug
Talazoparib Drug
Tiragolumab Drug
Trastuzumab emtansine Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 19, 2021
Primary completion: Sep 30, 2026
Completion: Sep 30, 2027
Last update posted: Mar 31, 2026

2021 – 2027

United States locations

U.S. sites: 21
U.S. states: 18
U.S. cities: 21

Facility	City	State	ZIP	Site status
City of Hope Comprehensive Cancer Center	Duarte	California	91010	Active, not recruiting
UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco	California	94143	Active, not recruiting
Medstar Georgetown Cancer Institute	Washington D.C.	District of Columbia	20007	Active, not recruiting
Mount Sinai Comprehensive Cancer Center	Miami Beach	Florida	33140	Active, not recruiting
University of Chicago	Chicago	Illinois	60637	Active, not recruiting
University of Kansas Cancer Center	Westwood	Kansas	66205	Active, not recruiting
Maine Medical Center	Scarborough	Maine	04074	Active, not recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02125	Active, not recruiting
University of Minnesota	Minneapolis	Minnesota	55455	Active, not recruiting
Washington University School of Medicine Siteman Cancer Center	St Louis	Missouri	63110	Withdrawn
Nebraska Methodist Hospital	Omaha	Nebraska	68114	Active, not recruiting
Englewood Health	Englewood	New Jersey	07631	Active, not recruiting
Atlantic Health Systems/Morristown Medical Center	Morristown	New Jersey	07960	Active, not recruiting
Roswell Park	Buffalo	New York	14263	Active, not recruiting
Weill Cornell Medicine	New York	New York	10065	Active, not recruiting
Duke University Cancer Center	Durham	North Carolina	27710	Active, not recruiting
University of Oklahoma Health Stephenson Cancer Center	Oklahoma City	Oklahoma	73104	Recruiting
Providence Portland Cancer Institute	Portland	Oregon	97213	Active, not recruiting
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15261	Active, not recruiting
Lifespan - Rhode Island Hospital	Providence	Rhode Island	02903	Active, not recruiting
Baptist Memorial Hospital	Memphis	Tennessee	38120	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04486352, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 31, 2026 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04486352 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →